Johnson & Johnson Stock Is Tumbling Tuesday: What Going On?

Comments
Loading...
Zinger Key Points

Johnson & Johnson Inc. JNJ shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan.

What To Know: U.S. Bankruptcy Court Judge Christopher Lopez rejected Johnson & Johnson’s prepackaged bankruptcy plan on Tuesday, sending shares of the pharmaceutical giant tumbling.

The plan was designed to resolve talc-related cancer claims, which Johnson & Johnson argues are baseless and fueled by plaintiff lawyers and outside investors. The settlement was supported by the overwhelming majority of claimants, according to Johnson & Johnson.

“The disclosures made under oath in the Red River bankruptcy affirmed that the talc litigation is a plaintiff-lawyer driven fake tort, premised on junk science and fueled by third party litigation financing including from foreign sovereign wealth funds. Consequently, the Company has no intent to settle or pay plaintiff lawyers on such meritless claims,” the company said.

Johnson & Johnson had previously set aside $7 billion for legal costs, but now plans to reverse that decision and fight the lawsuits in court.

Johnson & Johnson's legal team stated that the ruling allows a few law firms with "financially conflicted motives" to block what they claim was a fair settlement. The company noted that it has won 16 of the last 17 ovarian cancer cases and will continue its defense in the traditional court system.

The rejected bankruptcy plan is the latest in a series of attempts by Johnson & Johnson to limit its liability in the ongoing talc-related litigation. The Department of Justice previously argued that the company's bankruptcy maneuver was a bad-faith effort to shield itself from claims without fully entering bankruptcy. Despite increasing its settlement offer to $9 billion in September, the legal battle continues, contributing to investor concerns and the stock's decline.

JNJ Price Action: Johnson & Johnson shares were down 7.58% at $153.29 at the time of writing, according to Benzinga Pro.

Read Next:

Image via Shutterstock.

JNJ Logo
JNJJohnson & Johnson
$151.982.21%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
62.11
Growth
50.74
Quality
26.46
Value
19.91
Price Trend
Short
Medium
Long
Got Questions? Ask
Which pharmaceutical stocks might benefit from JNJ's decline?
How will litigation financing firms be impacted by this ruling?
Are there healthcare ETFs worth exploring after JNJ's drop?
What does JNJ's setback mean for talc suppliers?
Could this affect investments in legal firms involved in similar cases?
How might competitors of Johnson & Johnson take advantage of this situation?
What implications does this have for investors in consumer health products?
Will JNJ's legal battles create opportunities for short-sellers?
What opportunities arise in biotech stocks due to JNJ's legal issues?
How could JNJ's situation influence investments in litigation insurance?
Market News and Data brought to you by Benzinga APIs

Posted In: